/

Società

J

Non verificato

J INTS BIO

Di cosa scriviamo

BiologiaEconomiaFarmaceuticaSanitàStart-up

7 comunicati stampa

Guarda tutti i comunicati

02/06/2025

Farmaceutica

Sanità

Biologia

J INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025

Fonte

Emittente

1.00

0

30/04/2025

Farmaceutica

Sanità

Finanza

Scienza

J INTS BIO Presents Research Results for Next-Generation Innovative Anticancer Therapeutics 'JIN-A02' and 'JIN-001' at AACR 2025

Fonte

Emittente

1.00

0

Press Release cover image

25/11/2024

Farmaceutica

Sanità

Economia

Start-up

Finanza

Biologia

J INTS BIO and MD Anderson Collaborate on the Development of Brain Tumor Treatment 'JIN-001' - Enhancing Radiation and Chemotherapy Efficacy

Fonte

Emittente

1.00

0

Press Release cover image

05/11/2024

Farmaceutica

Sanità

Economia

Start-up

Biologia

J INTS BIO Launches AI-Supercomputing Alliance to Transform Cancer Therapy

Fonte

Emittente

1.00

0

Press Release cover image

24/10/2024

Farmaceutica

Sanità

Biologia

J INTS BIO Presents Interim Findings from Phase 1/2 Clinical Trial of 4th-Generation EGFR-TKI 'JIN-A02' in NSCLC: A Potential Breakthrough in Overcoming Acquired Resistance to Targeted Therapy

Fonte

Emittente

1.00

0

Press Release cover image

24/10/2024

Farmaceutica

Sanità

Finanza

Biologia

J INTS BIO Presents Interim Results from the Preclinical Study of 'JIN-001' in Refractory Ovarian Cancer: A Promising Solution for Overcoming Drug Resistance

Fonte

Emittente

1.00

0

Press Release cover image

10/06/2024

Farmaceutica

Sanità

Biologia

J INTS BIO, ASCO 2024 - JIN-A02 showed tumor reductions including brain metastasis in the ongoing first-in-human, dose-finding Phase 1 clinical study

Fonte

Emittente

1.00

0

Seguaci

0

Compatibilità

0